The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Molecular biomarkers of Alzheimer's disease: progress and prospects
Open accessAbstract
The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse and neuronal loss. This leads to clinical symptoms, such as progressive memory deficits. Clinically, these pathological changes can be detected in the cerebrospinal fluid and with brain imaging, although reliable blood tests for plaque and tangle pathologies remain to be developed. Plaques and tangles often co-exist with other brain pathologies, including aggregates of transactive response DNA-binding protein 43 and Lewy bodies, but the extent to which these contribute to the severity of Alzheimer's disease is currently unknown. In this ‘At a glance’ article and poster, we summarise the molecular biomarkers that are being developed to detect Alzheimer's disease and its related pathologies. We also highlight the biomarkers that are currently in clinical use and include a critical appraisal of the challenges associated with applying these biomarkers for diagnostic and prognostic purposes of Alzheimer's disease and related neurodegenerative disorders, also in their prodromal clinical phases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“…of a genetic link between AD and variants of the triggering receptor expressed on myeloid cells 2 ( TREM2 ; TREML2 ) gene (Guerreiro et al., 2013; Jonsson et al., 2013), which is selectively expressed on microglia in the CNS (Lue et al., 2015; Takahashi et al., 2005), has reignited the interest…”
Strimbu, K., & Tavel, J. A. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833ed177 · Cited by 2,062
Research works printed but not linked: 66
- Abdelnour, 2016, Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia, Mov. Disord., 31, 1203, 10.1002/mds.26668 · DOI
- Andreasson, 2016, Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders, Alzheimers Dement., 3, 98, 10.1016/j.dadm.2016.05.005 · DOI
- Barbour, 2008, Red blood cells are the major source of alpha-synuclein in blood, Neurodegener. Dis., 5, 55, 10.1159/000112832 · DOI · Paper page
- Blennow, 2006, Alzheimer's disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
- Brinkmalm, 2014, SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease, Mol. Neurodegener., 9, 53, 10.1186/1750-1326-9-53 · DOI · Paper page
- Burnham, 2016, Predicting Alzheimer disease from a blood-based biomarker profile: a 54-month follow-up, Neurology, 87, 1093, 10.1212/WNL.0000000000003094 · DOI
- Chhatwal, 2016, Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly, Neurology, 87, 920, 10.1212/WNL.0000000000003050 · DOI · Paper page
- Corrêa, 2011, Chemokines in CSF of Alzheimer's disease patients, Arq. Neuropsiquiatr., 69, 455, 10.1590/S0004-282X2011000400009 · DOI
- De Vos, 2015, C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease, Alzheimers Dement., 11, 1461, 10.1016/j.jalz.2015.05.012 · DOI
- Feneberg, 2014, Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases, Amyotroph. Lateral Scler. Frontotemporal. Degener., 15, 351, 10.3109/21678421.2014.905606 · DOI
- Fodero-Tavoletti, 2009, In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies, Eur. J. Pharmacol., 617, 54, 10.1016/j.ejphar.2009.06.042 · DOI
- Galimberti, 2006, Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration, Neurology, 66, 146, 10.1212/01.wnl.0000191324.08289.9d · DOI
- Hall, 2012, Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders, Arch. Neurol., 69, 1445, 10.1001/archneurol.2012.1654 · DOI · Paper page
- Hansson, 2014, Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease, Alzheimers Res. Ther., 6, 25, 10.1186/alzrt255 · DOI · Paper page
- Hellwig, 2015, Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease, Alzheimers Res. Ther., 7, 74, 10.1186/s13195-015-0161-y · DOI
- Hesse, 2001, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett., 297, 187, 10.1016/S0304-3940(00)01697-9 · DOI · Paper page
- Jack, 2013, Biomarker modeling of Alzheimer's disease, Neuron, 80, 1347, 10.1016/j.neuron.2013.12.003 · DOI · Paper page
- James, 2016, TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia, Brain, 139, 2983, 10.1093/brain/aww224 · DOI · Paper page
- Kaneko, 2014, Novel plasma biomarker surrogating cerebral amyloid deposition, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 90, 353, 10.2183/pjab.90.353 · DOI
- Kapaki, 2013, The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease, PLoS ONE, 8, e81654, 10.1371/journal.pone.0081654 · DOI
- Kester, 2015, Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease, JAMA Neurol., 72, 1275, 10.1001/jamaneurol.2015.1867 · DOI · Paper page
- Kikuchi, 2010, In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy, Brain, 133, 1772, 10.1093/brain/awq091 · DOI
- Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 10.1002/ana.20009 · DOI · Paper page
- Kolb, 2017, Tau positron emission tomography imaging, Cold Spring Harb. Perspect. Biol., 9, a023721, 10.1101/cshperspect.a023721 · DOI
- Kovacs, 2016, Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine, Int. J. Mol. Sci., 17, 189, 10.3390/ijms17020189 · DOI · Paper page
- Kuhlmann, 2016, CSF Abeta1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation, Clin. Chim. Acta, 467, 27, 10.1016/j.cca.2016.05.014 · DOI
- Kvartsberg, 2015, Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease, Alzheimers Dement., 11, 1180, 10.1016/j.jalz.2014.10.009 · DOI · Paper page
- Kvartsberg, 2015, Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls, Alzheimers Res. Ther., 7, 40, 10.1186/s13195-015-0124-3 · DOI
- Lagarde, 2017, In vivo PET imaging of neuroinflammation in Alzheimer's disease, J. Neural. Transm. (Vienna), 125, 847, 10.1007/s00702-017-1731-x · DOI
- Lashley, 2008, Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients, Acta Neuropathol., 115, 417, 10.1007/s00401-007-0336-0 · DOI · Paper page
- Magdalinou, 2015, A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes, J. Neurol. Neurosurg. Psychiatry, 86, 1240, 10.1136/jnnp-2014-309562 · DOI · Paper page
- Marquié, 2015, Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue, Ann. Neurol., 78, 787, 10.1002/ana.24517 · DOI · Paper page
- Mattsson, 2016, Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 87, 1000, 10.1136/jnnp-2015-311321 · DOI
- Mattsson, 2017, (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease, EMBO Mol. Med., 9, 1212, 10.15252/emmm.201707809 · DOI · Paper page
- Mollenhauer, 2010, Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies, Biomark. Med., 4, 683, 10.2217/bmm.10.90 · DOI
- Mollenhauer, 2011, alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, Lancet Neurol., 10, 230, 10.1016/S1474-4422(11)70014-X · DOI · Paper page
- Morbelli, 2018, Amyloid PET imaging: standardization and integration with other Alzheimer's disease biomarkers, Methods Mol. Biol., 1750, 203, 10.1007/978-1-4939-7704-8_13 · DOI
- Oeckl, 2016, Alpha-, Beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and Creutzfeldt-Jakob disease but no alteration in synucleinopathies, Mol. Cell. Proteomics, 15, 3126, 10.1074/mcp.M116.059915 · DOI
- Öhrfelt, 2009, Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?, Neurosci. Lett., 450, 332, 10.1016/j.neulet.2008.11.015 · DOI · Paper page
- Öhrfelt, 2016, Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone, Mult. Scler., 22, 1587, 10.1177/1352458515624558 · DOI
- Olsson, 2013, Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia, J. Alzheimers Dis., 33, 45, 10.3233/JAD-2012-120787 · DOI
- Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol., 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
- Payoux, 2017, New PET markers for the diagnosis of dementia, Curr. Opin. Neurol., 30, 606, 10.1097/WCO.0000000000000489 · DOI
- Peluso, 2017, Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection, AIDS, 31, 247, 10.1097/QAD.0000000000001314 · DOI
- Portelius, 2015, Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease, Brain, 138, 3373, 10.1093/brain/awv267 · DOI · Paper page
- Ramont, 2005, Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice, Clin. Chem. Lab. Med., 43, 1215, 10.1515/CCLM.2005.210 · DOI · Paper page
- Represa, 1990, Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate, J. Neurosci., 10, 3782, 10.1523/JNEUROSCI.10-12-03782.1990 · DOI · Paper page
- Schmidt, 2015, The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data, Alzheimers Dement., 11, 1050, 10.1016/j.jalz.2014.09.004 · DOI
- Schneider, 2009, The neuropathology of probable Alzheimer disease and mild cognitive impairment, Ann. Neurol., 66, 200, 10.1002/ana.21706 · DOI · Paper page
- Schott, 2012, Alzheimer's disease: mimics and chameleons, Pract. Neurol., 12, 358, 10.1136/practneurol-2012-000315 · DOI
- Shahnawaz, 2016, Development of a biochemical diagnosis of Parkinson disease by detection of alpha-Synuclein misfolded aggregates in cerebrospinal fluid, JAMA Neurol., 74, 163, 10.1001/jamaneurol.2016.4547 · DOI · Paper page
- Simonsen, 2017, Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia, Alzheimers Dement., 13, 274, 10.1016/j.jalz.2016.09.008 · DOI · Paper page
- Smailagic, 2015, (1)(8)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst. Rev., 1, CD010632, 10.1002/14651858.CD010632.pub2 · DOI · Paper page
- Steinacker, 2016, Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease, Sci. Rep., 6, 38737, 10.1038/srep38737 · DOI
- Tarawneh, 2016, Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease, JAMA Neurol., 73, 561, 10.1001/jamaneurol.2016.0086 · DOI · Paper page
- Tokuda, 2010, Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b · DOI · Paper page
- van Eijk, 2010, CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease, J. Alzheimers Dis., 21, 569, 10.3233/JAD-2010-090649 · DOI
- Voyle, 2015, Blood protein markers of neocortical amyloid-beta burden: a candidate study using SOMAscan technology, J. Alzheimers Dis., 46, 947, 10.3233/JAD-150020 · DOI
- Wallin, 2010, CSF biomarkers predict a more malignant outcome in Alzheimer disease, Neurology, 74, 1531, 10.1212/WNL.0b013e3181dd4dd8 · DOI · Paper page
- Watabe-Rudolph, 2012, Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease, Neurology, 78, 569, 10.1212/WNL.0b013e318247caa1 · DOI
- Westwood, 2016, Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly, J. Alzheimers Dis., 52, 561, 10.3233/JAD-151155 · DOI
- Winblad, 2016, Defeating Alzheimer's disease and other dementias: a priority for European science and society, Lancet Neurol., 15, 455, 10.1016/S1474-4422(16)00062-4 · DOI · Paper page
- Winston, 2016, Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile, Alzheimers Dement., 3, 63, 10.1016/j.dadm.2016.04.001 · DOI · Paper page
- Yin, 2009, Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions, J. Neurosci. Res., 87, 2578, 10.1002/jnr.22081 · DOI
- Zetterberg, 2015, Plasma amyloid beta-quo vadis?, Neurobiol. Aging, 36, 2671, 10.1016/j.neurobiolaging.2015.07.021 · DOI
- Zetterberg, 2013, Plasma tau levels in Alzheimer's disease, Alzheimers Res. Ther., 5, 9, 10.1186/alzrt163 · DOI · Paper page
Cited by
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Self-citationBiomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values
Dhama, K., Latheef, S. K., Dadar, M., Samad, H. A., Munjal, A., Khandia, R., Karthik, K., Tiwari, R., Yatoo, M. I., Bhatt, P., et al. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00091 · Cited by 321
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Metadata
- Authors
- Lashley, T., Schott, J. M., Weston, P., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M., Toombs, J., Rohrer, J. D., Heslegrave, A., & Zetterberg, H.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2018-05-01
- Volume
- 11
- Issue
- 5
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2799819209
- Cited by
- 230
- References
- 52
- FWCI
- 19.45
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Vetenskapsrådet
- Medical Research Council (MR/M008525/1)
- European Research Council
- Knut och Alice Wallenbergs Stiftelse
- Alzheimer's Research Trust
- Alzheimer's Association
- Swedish State Support for Clinical Research
- Wellcome Trust
- Leonard Wolfson Experimental Neurology Centre (MR/M008525/1)
- National Institute for Health Research (BRC149/NS/MH)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular biomarkers of Alzheimer's disease: progress and prospects. https://app.cochat.ai/papers/10.1242/dmm.031781
- The paper
- Lashley, T., Schott, J. M., Weston, P., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M., Toombs, J., Rohrer, J. D., Heslegrave, A., & Zetterberg, H. (2018). Molecular biomarkers of Alzheimer's disease: progress and prospects. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.031781
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.